VKTX Stock Recent News

While most investors pile into Eli Lilly (LLY 2.95%) or flee from struggling Novo Nordisk (NVO 2.48%), they're missing a compelling opportunity in the clinical-stage space. Novo recently lost nearly $70 billion in market cap after cutting 2025 guidance and warning of slowing Wegovy momentum, while the broader biotech industry's recent reawakening has created pockets of value among companies with differentiated approaches to weight management.

Recent history has, once again, demonstrated that relatively small biotech companies can see their shares soar significantly on positive developments. Summit Therapeutics' stock is up by more than 2,000% over the past three years, and Abivax, a France-based drugmaker, is up by more than 800% this year following strong clinical data.

The healthcare industry has been a remarkable place for investors to build significant portfolio returns through the years. Companies that are providing life-saving medicines, devices, and other products are often at the forefront of innovation in the healthcare space, a durable industry that tends to be broadly resilient even in times of economic unrest.

Explore the exciting world of Viking Therapeutics (VKTX 0.28%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

Viking Therapeutics' stock has outperformed the S&P 500 since its April lows, marking a solid turnaround. The company's dual-track approach (injectables and oral) for VK2735 positions it well against leaders Eli Lilly and Novo Nordisk, as recent results show solid progress. Strong liquidity position provides a reasonable cash runway through 2027, supporting R&D initiatives and upcoming key clinical data releases.

Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Company Participants Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer Conference Call Participants Stephanie Diaz - Vida Strategic Partners, Inc. Ryan Deschner - Raymond James & Associates, Inc., Research Division Joon Lee - Truist Securities, Inc., Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Hardik Parikh - JPMorgan Chase & Co, Research Division Michael Ulz - Morgan Stanley, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Jiale Song - Jefferies LLC, Research Division Biren Amin - Piper Sandler & Co., Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C.

Viking Therapeutics Posts Wider Q2 Loss

Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Registration Trials Underway for VK2735 in Obesity Phase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25 Continued Progress with Amylin Program; IND Planned 4Q25 Strong Quarter-End Cash Position of $808 Million SAN DIEGO , July 23, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2025, and provided an update on its clinical pipeline and other corporate developments.

Eli Lilly (LLY -1.24%) and Viking Therapeutics (VKTX -0.12%) have garnered considerable attention over the past year due to their solid clinical progress. However, these drugmakers have also lagged the market over the trailing-12-month period.